Special Issue "Bioactive Compounds from Marine Invertebrates"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 March 2014)

Special Issue Editor

Guest Editor
Dr. Kirsten Benkendorff
Marine Ecology Research Centre, Southern Cross University, PO Box 157, Military Road, Lismore NSW 2480, Australia
Website: http://www.scu.edu.au/marine-ecology/index.php/15
E-Mail: Kirsten.benkendorff@scu.edu.au
Phone: +61 2 66203755
Fax: +61 2 66212669
Interests: bioresource value of marine molluscs

Special Issue Information

Dear Colleagues,

All major lineages of invertebrates evolved in the oceans, and as such, the marine environment harbors the largest diversity of invertebrate phyla and species. As part of the struggle for survival, all extant marine invertebrate species occupy a unique niche within the marine environment, with specific adaptations to withstand a wide range of abiotic and biotic pressures. Many of these marine invertebrates are sessile or slow moving, and lack physical defense structures to protect against potential predators and competitors. They all also lack adaptive immunity against pathogens and parasites, despite being constantly bathed in microorganisms, and thus rely entirely on effective innate immune systems to keep themselves free of infection. To compensate for these apparent deficiencies, marine invertebrates have developed an arsenal of bioactive secondary metabolites. In addition to these chemically mediated defense interactions, some marine invertebrates use water soluble secondary metabolites for chemical communication (pheromones, settlement cues) and neurotoxins (in venoms) to paralyze or kill their prey.

Many of these intrinsically biologically active compounds produced by marine invertebrates provide useful leads for pharmaceutical, nutraceutical, and other industrial (e.g., anti-fouling) development. However, sustainable production is often limited by molecular complexity, which can limit economical chemical synthesis. Further insight into the ecology of the source species is required, including knowledge of the biosynthetic origin of the bioactive compounds, so as to distinguish innately synthesized, dietary derived or symbiotic microbial sources for sustainable culture. Investigation into the diversity and function of marine invertebrate secondary metabolites is also a vital step towards developing a comprehensive understanding of how chemicals might help structure marine populations, communities, and ecosystems.

In this special issue, we hope to explore all aspects of bioactive secondary metabolism in marine invertebrates, including the chemical diversity within certain invertebrate taxa, chemical ecology research aimed at elucidating the natural function of bioactive secondary metabolites, and the neuroecology of marine natural products, as well as bioactivity profiles, biosynthesis, and/or biodistributional studies on specific marine invertebrate natural products. We would also be interested in highlighting recent innovative research on the sustainable production, biomedical or industrial, of marine invertebrate natural products, or research into the traditional use of marine invertebrates that produce bioactive compounds. We welcome the submission of comprehensive/mini reviews, original research articles, and communications.

As guest editor, I invite you to contribute to the Marine Drugs special issue on “Bioactive Compounds from Marine Invertebrates”.

Dr. Kirsten Benkendorff
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).

Keywords

  • ascidian secondary metabolites
  • sponge secondary metabolites
  • cnidarian secondary metabolites
  • mollusc secondary metabolites
  • echinoderm secondary metabolites
  • chemical defense
  • marine chemical ecology
  • antimicrobial activity
  • antiviral activity
  • anti-inflammatory activity
  • anticancer activity
  • neurotoxin
  • pheromone
  • sustainable supply

Published Papers (13 papers)

Mar. Drugs 2014, 12(4), 2182-2204; doi:10.3390/md12042182
Received: 23 January 2014; in revised form: 20 March 2014 / Accepted: 21 March 2014 / Published: 10 April 2014
Show/Hide Abstract | Download PDF Full-text (1301 KB) | Download XML Full-text
abstract graphic

Mar. Drugs 2014, 12(4), 2114-2131; doi:10.3390/md12042114
Received: 10 December 2013; in revised form: 27 February 2014 / Accepted: 12 March 2014 / Published: 4 April 2014
Show/Hide Abstract | Download PDF Full-text (2061 KB) | Download XML Full-text
abstract graphic

Mar. Drugs 2014, 12(4), 2004-2018; doi:10.3390/md12042004
Received: 11 December 2013; in revised form: 29 January 2014 / Accepted: 7 February 2014 / Published: 2 April 2014
Show/Hide Abstract | Download PDF Full-text (907 KB) | Download XML Full-text

Mar. Drugs 2014, 12(4), 1987-2003; doi:10.3390/md12041987
Received: 23 January 2014; in revised form: 2 March 2014 / Accepted: 13 March 2014 / Published: 2 April 2014
Show/Hide Abstract | Download PDF Full-text (970 KB) | Download XML Full-text
abstract graphic

Mar. Drugs 2014, 12(3), 1569-1579; doi:10.3390/md12031569
Received: 24 December 2013; in revised form: 15 January 2014 / Accepted: 6 February 2014 / Published: 14 March 2014
Show/Hide Abstract | Download PDF Full-text (797 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2014, 12(2), 840-850; doi:10.3390/md12020840
Received: 12 November 2013; in revised form: 13 December 2013 / Accepted: 17 January 2014 / Published: 28 January 2014
Show/Hide Abstract | Download PDF Full-text (921 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2014, 12(2), 700-718; doi:10.3390/md12020700
Received: 21 November 2013; in revised form: 7 January 2014 / Accepted: 8 January 2014 / Published: 27 January 2014
Show/Hide Abstract | Download PDF Full-text (1323 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2014, 12(2), 672-681; doi:10.3390/md12020672
Received: 25 November 2013; in revised form: 10 December 2013 / Accepted: 13 January 2014 / Published: 27 January 2014
Show/Hide Abstract | Download PDF Full-text (681 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files
abstract graphic

Mar. Drugs 2014, 12(1), 232-254; doi:10.3390/md12010232
Received: 5 November 2013; in revised form: 23 December 2013 / Accepted: 30 December 2013 / Published: 9 January 2014
Show/Hide Abstract | Download PDF Full-text (668 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Mar. Drugs 2014, 12(1), 214-231; doi:10.3390/md12010214
Received: 19 October 2013; in revised form: 20 December 2013 / Accepted: 23 December 2013 / Published: 9 January 2014
Show/Hide Abstract | Download PDF Full-text (1335 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2013, 11(12), 5024-5035; doi:10.3390/md11125024
Received: 15 October 2013; in revised form: 25 November 2013 / Accepted: 27 November 2013 / Published: 11 December 2013
Show/Hide Abstract | Download PDF Full-text (967 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2013, 11(12), 4917-4936; doi:10.3390/md11124917
Received: 24 September 2013; in revised form: 18 November 2013 / Accepted: 19 November 2013 / Published: 10 December 2013
Show/Hide Abstract | Download PDF Full-text (1308 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Mar. Drugs 2013, 11(10), 3735-3741; doi:10.3390/md11103735
Received: 27 August 2013; in revised form: 11 September 2013 / Accepted: 24 September 2013 / Published: 30 September 2013
Show/Hide Abstract | Download PDF Full-text (500 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Last update: 22 August 2013

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert